Recent Advances in the Development of Membrane-derived Vesicles for Cancer Immunotherapy
Copyright© Bentham Science Publishers; For any queries, please email at epubbenthamscience.net..
The surface proteins on cell membranes enable the cells to have different properties, such as high biocompatibility, surface modifiability, and homologous targeting ability. Cell-membrane-derived vesicles have features identical to those of their parental cells, which makes them one of the most promising materials for drug delivery. Recently, as a result of the impressive effects of immunotherapy in cancer treatment, an increasing number of researchers have used cell-membrane-derived vesicles to enhance immune responses. To be more specific, the membrane vesicles derived from immune cells, tumor cells, bacteria, or engineered cells have the antigen presentation capacity and can trigger strong anti-tumor effects of the immune system. In this review, we first indicated a brief description of the vesicles and then introduced the detection technology and drug-loading methods for them. Secondly, we concluded the characteristics and applications of vesicles derived from different sources in cancer immunotherapy.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 2023 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:21 |
|---|---|
| Enthalten in: |
Current drug delivery - 21(2023), 3 vom: 01., Seite 403-420 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Xiao, Yuai [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Cancer immunotherapy |
|---|
| Anmerkungen: |
Date Completed 23.11.2023 Date Revised 23.11.2023 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.2174/1567201820666230504120841 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM356465020 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM356465020 | ||
| 003 | DE-627 | ||
| 005 | 20231226070524.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.2174/1567201820666230504120841 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1188.xml |
| 035 | |a (DE-627)NLM356465020 | ||
| 035 | |a (NLM)37143265 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Xiao, Yuai |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Recent Advances in the Development of Membrane-derived Vesicles for Cancer Immunotherapy |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 23.11.2023 | ||
| 500 | |a Date Revised 23.11.2023 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright© Bentham Science Publishers; For any queries, please email at epubbenthamscience.net. | ||
| 520 | |a The surface proteins on cell membranes enable the cells to have different properties, such as high biocompatibility, surface modifiability, and homologous targeting ability. Cell-membrane-derived vesicles have features identical to those of their parental cells, which makes them one of the most promising materials for drug delivery. Recently, as a result of the impressive effects of immunotherapy in cancer treatment, an increasing number of researchers have used cell-membrane-derived vesicles to enhance immune responses. To be more specific, the membrane vesicles derived from immune cells, tumor cells, bacteria, or engineered cells have the antigen presentation capacity and can trigger strong anti-tumor effects of the immune system. In this review, we first indicated a brief description of the vesicles and then introduced the detection technology and drug-loading methods for them. Secondly, we concluded the characteristics and applications of vesicles derived from different sources in cancer immunotherapy | ||
| 650 | 4 | |a Review | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Drug delivery | |
| 650 | 4 | |a cancer immunotherapy | |
| 650 | 4 | |a extracellular vesicles | |
| 650 | 4 | |a immune response | |
| 650 | 4 | |a nanovesicles | |
| 650 | 4 | |a therapeutic agents. | |
| 700 | 1 | |a Wu, Minliang |e verfasserin |4 aut | |
| 700 | 1 | |a Xue, Chunyu |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Yuchong |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Current drug delivery |d 2004 |g 21(2023), 3 vom: 01., Seite 403-420 |w (DE-627)NLM159100232 |x 1875-5704 |7 nnns |
| 773 | 1 | 8 | |g volume:21 |g year:2023 |g number:3 |g day:01 |g pages:403-420 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.2174/1567201820666230504120841 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 21 |j 2023 |e 3 |b 01 |h 403-420 | ||